GRFS News and Press, Grifols S.A. From 09/13/20

Investment Thesis CSL Limited ( CSLLY ) has yet to fully recover from the plasma shortages experienced during the lockdowns. The impact on production is likely to materialize just as elective surgeries resume. The influenza vaccine sales can pick up the slack as fears mount over a flu outb...

Grifols (NASDAQ: GRFS )  has entered into an agreement to acquire the remaining equity of Alkahest in exchange for a total price of $146M, on a debt-free basis. No additional financing will be required. More news on: Grifols, S.A., Healthcare stocks news, Read more ...

"Convalescent plasma should not be considered standard of care for the treatment of patients with COVID-19," says the NIH . "There are currently no data from well-controlled, adequately powered randomized clinical trials that demonstrate the efficacy and safety of convalescent plasma for th...

The chief of the FDA is willing to bypass the full federal approval process in order to make a COVID-19 vaccine available as soon as possible. More news on: Kamada Ltd., Grifols, S.A., XBiotech Inc., Healthcare stocks news Read more ...

Investors in convalescent plasma players have experienced a bit of volatility of late related to the FDA emergency use nod to treat COVID-19 patients. More news on: Kamada Ltd., Grifols, S.A., XBiotech Inc., Healthcare stocks news, Read more ...

Sonnet BioTherapeutics Holdings (NASDAQ: SONN ) +67%  on FDA nod for convalescent plasma. More news on: Sonnet BioTherapeutics Holdings, Inc., Liminal BioSciences Inc., ADMA Biologics, Inc., Stocks on the move, , Read more ...

"On the therapeutics front...in our battle against the China virus that will save countless lives, the FDA has issued an emergency use authorization — and that's such powerful term, emergency use authorization — for a treatment known as convalescent plasma," President Trump s...

This article is part of a series that provides an ongoing analysis of the changes made to George Soros's 13F stock portfolio on a quarterly basis. It is based on George Soros's regulatory 13F Form filed on 08/14/2020. Please visit our Tracking Soros Fund Management Holdings article for an ...

Processors of antibody-rich convalescent plasma, derived from COVID-19 patients who have recovered from the infection, are under the gun on a delay of the expected emergency use authorization from the FDA for the treatment of COVID-19. More news on: Kamada Ltd., Grifols, S.A., XBiotech I...

Results from a large-scale study involving more than 35K severely ill COVID-19 patients demonstrated that the early administration of convalescent plasma, derived from patients who recovered from the infection and who generated antibodies against SARS-CoV-2, lowered the mortality rate. ...